Can Eczema Medicines Be Tapered? Evidence From 19 Studies and 4,375 Patients

November 9, 2026

AI-generated illustration: Dr. Arsy Hydration Barrier Ritual

Medically reviewed research summary. Educational only; not individualized medical advice.

Why tapering is being studied

When moderate-to-severe eczema is controlled with a biologic or oral targeted medicine, patients often ask whether the dose can be reduced. A systematic review examined 19 studies involving 4,375 patients treated with dupilumab, tralokinumab, lebrikizumab, abrocitinib, baricitinib or upadacitinib.

What the review found

Reported sustained-response proportions varied widely: 0% to 60% for abrocitinib, 45% to 61% for baricitinib, 30% to 100% for dupilumab, 67% to 82% for lebrikizumab, 25% to 50% for tralokinumab and 47% to 61% for upadacitinib. Lower disease activity before tapering and earlier improvement appeared repeatedly as possible predictors. Selected studies also identified drug-specific signals, but those findings were not uniform enough to serve as a universal rule.

Why the ranges are so broad

The included studies used different definitions of control, tapering schedules, withdrawal rules, follow-up periods and rescue treatments. Some were randomized trials; others were observational cohorts prone to selection bias. People chosen for tapering may already have unusually stable disease. A percentage from one regimen should not be applied to a different drug or person.

Tapering is not the same as stopping suddenly

The review suggested that carefully reduced dosing preserved control more often than abrupt withdrawal in selected patients, but the evidence was heterogeneous. Targeted medicines have distinct pharmacology and safety considerations. Stopping an oral JAK inhibitor, spacing injections or changing background topical therapy are not interchangeable strategies.

Safety-first decisions

Do not reduce, interrupt or restart a systemic eczema medicine without the prescriber. Clinicians may consider prior severity, stability over multiple visits, itch, sleep, quality of life, comorbidities, access to follow-up and a rescue plan. Relapse can occur even after apparently durable control. Children require specialist oversight; adult tapering data cannot be presumed safe for babies.

Bottom line

Tapering may be reasonable for carefully selected, stable patients, but there is no one-size-fits-all schedule. The review supports structured monitoring and shared decision-making—not self-directed dose changes.

Continue the research

References

← Back to Doctor's Notes